186584-73-6

Basic information

• Product Name: 2-FLUORO-5-IODOBENZOYL CHLORIDE
• Synonyms: 2-FLUORO-5-IODOBENZOYL CHLORIDE
• CAS NO: 186584-73-6
• Molecular Formula: C₇H₃ClFIO
• Molecular Weight: 284.45
• Product Categories: Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 186584-73-6.mol

Chemical Properties

• Melting Point: 30-34 °C(lit.)
• Boiling Point: 269.1 °C at 760 mmHg
• Flash Point: 139 °F
• Appearance: /
• Density: 2.001 g/cm³
• Vapor Pressure: 0.00738mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Sensitive: Moisture & Light Sensitive
• CAS DataBase Reference: 2-FLUORO-5-IODOBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-5-IODOBENZOYL CHLORIDE(186584-73-6)
• EPA Substance Registry System: 2-FLUORO-5-IODOBENZOYL CHLORIDE(186584-73-6)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 186584-73-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-FLUORO-5-IODOBENZOYL CHLORIDE is used as a reactant for the preparation of biologically and pharmacologically active molecules. Its unique structure allows for the synthesis of various compounds with potential therapeutic properties.
Used in Organic Synthesis:
2-FLUORO-5-IODOBENZOYL CHLORIDE is used as a reactant in microwave-assisted boron trichloride mediated coupling reactions. This method enhances the efficiency and speed of the synthesis process, making it a valuable tool in the development of new organic compounds.

InChI:InChI=1/C7H3ClFIO/c8-7(11)5-3-4(10)1-2-6(5)9/h1-3H

Upstream product

• 124700-41-0 2-fluoro-5-iodobenzoic acid 
• 445-29-4 o-fluoro-benzoic acid 

Downstream Products

• 697762-43-9 ethyl 3-(dimethylamino)-2-[(2-fluoro-5-iodophenyl)carbonyl]-2-propenoate 
• 882678-76-4 2-fluoro-5-iodo-N-(3-(trifluoromethyl)phenyl)benzamide 
• 926036-44-4 N-(2-((3-(dimethylamino)propyl)(methyl)amino)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-45-5 N-(2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-50-2 (R)-N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-51-3 (S)-N-(2-(3-(dimethylamino)pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-46-6 N-(2-(4-(dimethylamino)piperidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-48-8 (S)-N-(2-(3-(dimethylamino)piperidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-47-7 (R)-N-(2-(3-(dimethylamino)piperidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 926036-37-5 (S)-tert-butyl 1-(2-(2-fluoro-5-iodobenzamido)-4-(trifluoromethyl)phenyl)piperidin-3-ylcarbamate 
• 884602-86-2 (S)-tert-butyl 1-(2-(2-fluoro-5-iodobenzamido)-4-(trifluoromethyl)phenyl)piperidine-3-carboxylate 
• 926036-43-3 2-fluoro-5-iodo-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide 
• 1016544-66-3 (2-fluoro-5-iodophenyl)(3,4,5-trimethoxyphenyl)methanone 
• 850892-33-0 (2-Fluoro-5-iodo-phenyl)-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-methanone 

Relevant articles and documents

Initial Scale-Up and Process Improvements for the Preparation of a Lead Antibacterial Macrolone Compound

Macrolones are a novel class of potent antimicrobial agents that consist of a macrolide scaffold to which a quinolone unit is tethered by various linkers to the 4 -O-position of the cladinose sugar. In this paper is described a modified 13-step route to a

Macrolide and carbostyril heterocomplex and preparation method thereof

The invention provides a macrolide and carbostyril heterocomplex. The macrolide and carbostyril heterocomplex is characterized by comprising compounds shown in the formula I and the formula II, or thecompounds shown in the formula I and the formula II and

Erythromycin derivative and preparing method thereof

The invention provides an erythromycin derivative. The erythromycin derivative is characterized by comprising a compound in a general formula I or comprising pharmaceutically-acceptable salt formed with the compound in the general formula I and inorganic

5-AROMATIC ALKYNYL SUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF

The present invention relates to the fields of pharmaceutical chemistry and drug therapy, and particularly relates to a compound of formula I, and a preparation method and use thereof as a negative allosteric modulator of a metabotropic glutamate receptor

4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phosphatase 1B

Protein tyrosine phosphatase 1B is a negative regulator in the insulin and leptin signaling pathways, and has emerged as an attractive target for the treatment of type 2 diabetes and obesity. However, the essential pharmacophore of charged phosphotyrosine or its mimetic confer low selectivity and poor cell permeability. Starting from our previously reported aryl diketoacid-based PTP1B inhibitors, a drug-like scaffold of 4-quinolone-3-carboxylic acid was introduced for the first time as a novel surrogate of phosphotyrosine. An optimal combination of hydrophobic groups installed at C-6, N-1 and C-3 positions of the quinolone motif afforded potent PTP1B inhibitors with low micromolar IC 50 values. These 4-quinolone-3-carboxylate based PTP1B inhibitors displayed a 2-10 fold selectivity over a panel of PTP's. Furthermore, the bidentate inhibitors of 4-quinolone-3-carboxylic acids conjugated with aryl diketoacid or salicylic acid were cell permeable and enhanced insulin signaling in CHO/hIR cells. The kinetic studies and molecular modeling suggest that the 4-quinolone-3-carboxylates act as competitive inhibitors by binding to the PTP1B active site in the WPD loop closed conformation. Taken together, our study shows that the 4-quinolone-3-carboxylic acid derivatives exhibit improved pharmacological properties over previously described PTB1B inhibitors and warrant further preclinical studies.

Design, synthesis and insecticidal activity of novel anthranilic diamides with benzyl sulfide scaffold

A series of novel anthranilic diamides with benzyl sulfide scaffold were synthesized, in which N-pyridylpyrazole moiety generally regarded as key pharmacophore was abandoned. The target compounds were characterized by 1H NMR, 13C NMR, 19F NMR and HRMS. The preliminary bioassays indicated that half of the title compounds were endowed with good insecticidal activities against armyworm (Mythimna sepatara) at the concentration of 500 mg/L. Exhilaratingly, the synthesized compound 3a was also active against Tetranychus cinnabarinus at 100 mg/L. The difference in activities between the target compounds was influenced by the substituents, which provided some hints for further investigation on structure modifications.

SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.

Synthesis and biological activity of 4″-O-acyl derivatives of 14- and 15-membered macrolides linked to ω-quinolone-carboxylic unit

The synthesis and antimicrobial activity of a new class of macrolide antibiotics which consist of a macrolide scaffold and a quinolone unit covalently connected by an appropriate linker are described. Optimization of several synthetic steps and structural

HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF

Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto - enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited-marked antiretroviral activity. Here, we show the synthesis and the detailed structure - activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3,3- dimethylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nMin the strand transfer assay and an ED50 of 0.6 nMin the antiviral assay, and 6-(3-chloro-2-fluorobenzyl) -1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid 49, which had an IC50 of 7.2 nMand an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrasecatalyzed strand transfer processes than 3′-processing reactions, as is the case with the keto - enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.